《氯吡格雷(波立维)在急性冠脉综合征治疗中的地位》-公开课件.pptVIP

* Slide 11 PCI-CURE – 30 Day Results Composite of cardiovascular death, MI, or urgent revascularization Treatment with clopidogrel on top of standard therapy (including ASA) resulted in a RRR of 30% (p=0.03) compared with standard therapy (including ASA) alone for the endpoint of cardiovascualr death, MI, or urgent revascularization at 30 days post-PCI. The event curves separated early and continued to separate out to 30 days and beyond. A reduction in this endpoint was observed within 2 days, with continuing benefit throughout the study period (up to 1 year). The majority of patients (80% in both groups) received open-label ADP-receptor antagonist following PCI, suggesting the early benefit was mainly due to clopidogrel pre-treatment. An “on-treatment” analysis which excluded those patients that received open-label ADP-receptor antagonist prior to PCI (~25% in both groups) demonstrated a 42% RRR (p=0.005) in this endpoint. Reference The CURE Trial Investigators. Effect of clopidogrel and aspirin pre-treatment followed by long term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study. Lancet August 2001. * Slide 12 PCI-CURE – 30 Day Results Treatment with clopidogrel on top of standard therapy (including ASA) resulted in a RRR of 30% (p=0.03) compared with standard therapy (including ASA) alone for the endpoint of cardiovascualr death, MI, or urgent revascularization at 30 days post-PCI. A reduction in this endpoint was observed within days, with continuing benefit on to 30 days throughout the 12 month study period. An “on-treatment” analysis which excluded those patients that received open-label ADP-receptor antagonist prior to PCI (~25% in both groups) demonstrated a 42% RRR (p=0.005) in this endpoint. For the treatment of cardiovascular death or MI, clopidogrel treatment resulted in a 34% relative risk reduction (p=0.04). Clopidogrel treatment was associated with particularly efficacious reductions large Q-wave MI.